[Hemodynamic and methabolic aspects of sodium nitroprusside pharmacodynamics during buccal administration in patients with arterial hypertension of cerebral ischemic genesis].

The authors presented in the article efficiency of new formulation of Natrium Nitroprusodum used buccaly in patients with cerebral-ischemic form of arterial hypertention and stage II hypertention. It has been shown both in an acute experiment and after monothrerapy having been used. The medication proved to have positive effect on brachiocephalic vessel blood flow indices in patients of both groups using pulse doplergraphy. The use of Natrium Nitroprussidum used buccaly in patients with cerebral-ischemic form of arterial hypertention and hyportensive disease differentiates in terms of indices characterising the formation, transport and utilisation of energetic products, products of POL and antioxidant ferments.

[Activation of the kallikrein-kinin system of the blood in hypertension and atherosclerosis with transient cerebral circulatory disorders]. / Aktivnost' kallikrein-kininovoi sistemy krovi u bol'nykh gipertonicheskoi bolezn'iu i aterosklerozom s prekhodiashchimi narusheniiami mozgovogo krovoobrashcheniia.

The authors studied the blood kinin system in patients with transient impairments of the cerebral circulation (TICC) both in the presence of hypertonic crises (30 patients) and cerebral vascular atherosclerosis (30 patients) during a vascular episode on the 10th-15th day of treatment. During TICC, the patients showed a marked activation of the blood kinin system which was especially pronounced in hypertonic rises. The underlying disease had a significant impact on the time-course of kinin system activity. In patients with TICC associated with hypertonic crises, hypotensive treatment decreased kinin activity to a considerable degree whereas in cases of cerebral vascular atherosclerosis the treatment exerted no noticeable effect on the activity of kinins. The involvement of kinins in the processes of the compensation and pathogenesis in TICC is discussed. It is recommended that TICC associated with arterial hypertension be treated by sodium salicylate, whereas in TICC associated with atherosclerosis the administration of antikinin drugs is indicated (parmidin, prodectin).